Pressure Sensitive Adhesive Means Patents (Class 424/448)
-
Publication number: 20080138388Abstract: It is intended to provide a transdermal absorption patch which is highly excellent in transdermal absorption properties and long-lasting drug effect even in the case where a drug-effect component contained in the transdermal absorption patch is a basic drug hardly soluble in a pressure-sensitive adhesive base, has a high stability of the drug contained therein with the passage of time and can achieve improvement in the compliance and simplification of the administration method. These problems can be solved by providing a transdermal absorption patch which contains a basic drug having an octanol/water partition coefficient (logarithm) in the free state of 3 or above, a pressure-sensitive adhesive base and a (meth)acrylic copolymer having carboxyl group.Type: ApplicationFiled: January 24, 2006Publication date: June 12, 2008Applicant: Hisamitsu Pharmaceutical Co., Inc.Inventors: Kazunosuke Aida, Yasunari Michinaka, Takaaki Terahara
-
Patent number: 7384650Abstract: A transdermal hormone delivery system (THDS) is disclosed. The THDS is useful for control of fertility and as therapy for a variety of diseases and conditions treatable by robust delivery of progestin and estrogen hormones, particularly the progestin, levonorgestrel. The THDS comprises a backing layer, an adjoining adhesive polymer matrix comprising an effective amount of at least a progestin hormone, delivery of which is enhanced by one or more skin permeation enhancing agents present in pre-determined amounts. The THDS is capable of providing effective daily doses of progestin and estrogen hormones from a small surface area in contact with the skin, e.g., less than 20 square centimeters. Methods of fertility control and various types of hormone replacement therapy utilizing the THDS are also disclosed.Type: GrantFiled: July 17, 2003Date of Patent: June 10, 2008Assignee: Agile Therapeutics, Inc.Inventor: Te-Yen Chien
-
Patent number: 7384651Abstract: A transdermal therapeutic system (TTS), in particular a patch, is described, comprising: a detachable protective layer; a pressure-sensitive adhesive reservoir layer; and a backing layer with or without a coating of pressure-sensitive adhesive and featuring a unidirectionally, preferably longitudinally, elastic material having an elasticity of at least 20%. The TTS is particularly suitable for use as a multi-day plaster for the treatment of, for instance, pain or drug dependency.Type: GrantFiled: July 15, 2004Date of Patent: June 10, 2008Assignee: LTS Lohmann Therapie-Systeme AGInventors: Thomas Hille, Lothar Deurer
-
Publication number: 20080131490Abstract: A donepezil-containing patch preparation is provided whereby production of donepezil-related substances in the pressure-sensitive adhesive layer is suppressed. A stabilizer comprising at least one or more species selected from the group consisting of ascorbic acid, metal salts or esters thereof, isoascorbic acid or metal salts thereof, ethylenediamine tetraacetic acid or metal salts thereof, cysteine, acetylcysteine, 2-mercaptobenzimidazole, 3(2)-t-butyl-4-hydroxyanisole, 2,6-di-t-butyl-4-methylphenol, tetrakis[3-(3?,5?-di-t-butyl-4?-hydroxyphenyl)propionic acid]pentaerythritol, 3-mercapto-1,2-propanediol, tocopherol acetate, rutin, quercetin, hydroquinone, metal salts of hydroxymethanesulfinic acid, metal metabisulfite salts, metal sulfite salts and metal thiosulfate salts is blended in a donepezil-containing pressure-sensitive adhesive layer provided on at least one side of a support.Type: ApplicationFiled: November 30, 2007Publication date: June 5, 2008Inventors: Akinori Hanatani, Junichi Sekiya, Sachiko Terashi, Sumiyo Nishi, Satoko Washiro, Hitoshi Akemi
-
Publication number: 20080131491Abstract: The present invention provides a percutaneously absorbable preparation for percutaneous absorption of donepezil or its hydrochloride which is stable and resistant to loss of cohesiveness of the pressure-sensitive adhesive layer while attached and resistant to adhesive transfer due to cohesive failure during removal by peeling. The percutaneously absorbable preparation comprises 2-[(1-benzyl-4-piperidinyl)methyl]-5,6-dimethoxyindan-1-on and/or its hydrochloride and a metal chloride in a pressure-sensitive adhesive layer which has been crosslinked.Type: ApplicationFiled: November 30, 2007Publication date: June 5, 2008Inventors: Akinori Hanatani, Satoko Washiro, Hitoshi Akemi
-
Publication number: 20080118544Abstract: The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. The additive has a hydrophilic part and a hydrophobic part and the therapeutic agent is not enclosed in micelles or encapsulated in particles or controlled release carriers.Type: ApplicationFiled: November 19, 2007Publication date: May 22, 2008Inventor: Lixiao Wang
-
Publication number: 20080113010Abstract: The present invention relates to nonaqueous preparation for percutaneous absorption prepared by laminating an adhesive layer comprising a nonsteroidal anti-inflammatory analgesic in an alkali metal salt form, and an inorganic acid which is strongly acidic compared with the nonsteroidal anti-inflammatory analgesic in a free form, together with a nonaqueous base, on a support. According to the present invention, drug-releasing characteristics and skin penetration in a nonaqueous preparation for percutaneous absorption can be improved because the addition of an inorganic acid in a nonaqueous base containing a drug in an alkali metal salt form leads to an improvement in the solubility of the drug in the base, and a good partitioning of the drug to skin surface. In addition, as the inorganic acid has no alcoholic hydroxy group in the structure, the inorganic acid does not react with the drug, therefore it causes no lowering in the stability of the drug by esterification.Type: ApplicationFiled: November 5, 2004Publication date: May 15, 2008Applicant: LEAD CHEMICAL CO., LTD.Inventors: Seijirou Yama, Naoki Murai
-
Publication number: 20080107718Abstract: The invention relates to a production process for a foam wound dressing having an external germ barrier, more particularly a film layer, and also to a wound dressing thus obtained, having, where appropriate, a pressure-sensitive adhesive layer. In the process according to the invention the germ barrier is produced by means of extrusion directly on the foam base. This results in a more reliable bond between foam layer and germ barrier, without detriment to the absorptiveness of the foam for wound exudate. The process presented is simple and cost-effective, and all of the requirements from the medical sector (e.g. absence of solvent) can be met.Type: ApplicationFiled: October 30, 2007Publication date: May 8, 2008Applicant: COLLANO AGInventors: Catherine Baron, Alfred Rasche, Fabian Leuthard, Adrian Schulthess, Andreas Dobmann, Manuel Leumann, Dirk Clasen
-
Publication number: 20080102107Abstract: Compositions suitable for use in treating pain and increasing range of motion of an affected joint of an animal, particularly a human. The compositions contain a transdermal delivery formulation for delivering effective amounts of glutamine, hyaluronic acid, methysulfonylmethane, and glucosamine to the affected joint. The compositions are applied topically to the skin area adjacent to the affected joint. Methods for treating pain and increasing range of motion that use the transdermal joint pain therapy compositions are also provided.Type: ApplicationFiled: December 16, 2005Publication date: May 1, 2008Applicant: Valex Pharmaceuticals, LLCInventors: Gary Lewellyn, J. Calvin Johnson, John Lassiter
-
Patent number: 7351426Abstract: This invention addresses absorbable cyanoacrylate-based tissue adhesive compositions based primarily on an alkoxy cyanoacrylate combined with one or more alkyl cyanoacrylate(s), a stabilizer against premature anionic polymerization, and/or an absorbable polymeric modifier with improved, and preferably, functional properties for use, primarily, for internal wound repair applications.Type: GrantFiled: March 3, 2004Date of Patent: April 1, 2008Assignee: Poly-Med, Inc.Inventors: Shalaby W. Shalaby, M. Aaron Vaughn
-
Patent number: 7344733Abstract: The invention relates to an active-ingredient-containing, matrix-controlled transdermal therapeutic system for the use of pramipexole, ropinirole, pharmaceutically acceptable salts thereof or pharmaceutically acceptable derivatives thereof.Type: GrantFiled: July 26, 2002Date of Patent: March 18, 2008Assignee: Hexal AGInventors: Cornelia Beier, Martina Wilhelm
-
Patent number: 7329417Abstract: A medical dressing comprising a complex of silver and being capable of releasing antimicrobial silver ion activity, the complex comprising silver ion, a transition element of Group IV of the periodic system of elements, cation, phosphate and hydrogen to enable a controlled release of silver ion activity to a wound bed.Type: GrantFiled: February 8, 2002Date of Patent: February 12, 2008Assignee: Coloplast A/SInventor: Brian Nielsen
-
Publication number: 20080019941Abstract: The present invention is directed towards the use and delivery of a therapeutic method and agent to reduce and prevent excessive scarring resulting from cellular contraction and/or excess accumulation of extracellular matrix by inhibition and/or inducement of smooth muscle actin (SMA) and/or tissue growth factor beta (TGF-?) in a tissue, organ or injury site.Type: ApplicationFiled: July 20, 2006Publication date: January 24, 2008Inventor: Susan J. Drapeau
-
Patent number: 7316817Abstract: A composite sheet for delivering therapeutic agents to the skin and method of use is disclosed. The composite sheet comprises a flexible porous polymer for holding and releasing the therapeutic agent in a polymer enrobing material. Micro-channels pass through the polymer enrobing material and flexible porous polymer to promote the release of the therapeutic agent. The composite sheet is capable of releasing the therapeutic agent for periods of up to about 14 to about 30 days.Type: GrantFiled: January 2, 2004Date of Patent: January 8, 2008Assignee: New Medical Technologies, Inc.Inventors: Haitham Matloub, Wilfred Lynch
-
Publication number: 20080003273Abstract: The present disclosure generally relates to compositions for reducing inflammation, and more particularly, to compositions comprising oleocanthal. The oleocanthal-containing compositions are particularly suitable for transdermal delivery. The compositions may also be used in combination with personal care products, such as wipes and absorbent articles, and may be incorporated into transdermal patches.Type: ApplicationFiled: June 29, 2006Publication date: January 3, 2008Applicant: KIMBERLY-CLARK WORLDWIDE, INC.Inventors: Joseph R. Feldkamp, David William Koenig, Scott W. Wenzel, Wael Joseph
-
Patent number: 7309498Abstract: A biodegradable microfiber absorbent comprises a substantially homogeneous mixture of at least one hydrophilic polymer and at least one biodegradable polymer. The absorbent can be prepared by an electro hydrodynamic spinning of a substantially homogeneous polymer mixture. Medical dressings for burns and wounds, cavity dressings, drug delivery patches, face masks, implants, drug carriers that comprises at least one microfiber electrospun from a polymer mixture are provided. The dressings can have variable water vapor penetration characteristics and variable biodegradation times.Type: GrantFiled: October 9, 2002Date of Patent: December 18, 2007Inventors: Bronislava G. Belenkaya, Valentina I. Sakharova, Vyacheslav N. Polevov
-
Patent number: 7303759Abstract: The invention described herein relates to methods for reducing and/or stopping bleeding or fluid loss from open wound, denuded tissue, or burned skin, comprising the step of applying to the open wound, denuded tissue or burned skin a gel-forming composition comprising at least one of the following compositions: a polyacrylic acid having the structural formula [CH2?CHCO2H]n, where n is between 10,000 and 70,000; a polyacrylic acid and a desiccated water soluble organic or inorganic base; polyacrylic acid and a desiccated poorly soluble basic salt, and a polyvinyl alcohol having the structural formula of [CH2?CHOH]n, where n is between 15,000 and 150,000.Type: GrantFiled: June 20, 2002Date of Patent: December 4, 2007Assignee: The United States of America as represented by the Secretary of the ArmyInventor: Millard Marsden Mershon
-
Patent number: 7288265Abstract: An adhesive patch is provided wherein the patch includes a porous backing having a front side and a back side. The patch also includes a therapeutic formulation located on the front side of the backing. The backing includes a flexible sheet of water insoluble porous material. The therapeutic formulation includes a combination of a antiviral agent useful for treating a viral infection in a mammal (e.g., human), a medicament that relieves topical discomfort, an adhesive, and a solvent. The solvent can preferably include a fragrance.Type: GrantFiled: January 8, 2003Date of Patent: October 30, 2007Assignee: LecTec CorporationInventor: David Rolf
-
Publication number: 20070248656Abstract: Topical preparation dispensers and methods of using the same are provided. Aspects of the invention include a topical preparation dispenser having a holder, one or more vertically stacked topical preparations in the holder, and a cap at one end of the holder configured such that upon movement of the cap, a topical preparation is exposed and moved relative to the holder. Also provided are kits that include the subject dispensers.Type: ApplicationFiled: March 27, 2007Publication date: October 25, 2007Inventor: Bradley S. Galer
-
Publication number: 20070243239Abstract: A patch is disclosed which is capable of dispensing a scent. The patch includes a pad impregnated with a liquid and the pad is located between a liquid-impermeable barrier layer and a vapor permeable carrier layer. An evaporative interface is situated between the pad and the carrier layer and represents a location where the liquid is transformed into a vapor as it contacts air. A plurality of vaporization ports extend from the evaporative interface to an upper surface of the carrier layer and provide an escape route through which the vapor can escape. The patch is designed to be housed in a package until it is ready to be used. When the package is opened, the patch will emit vapors which are released into the surrounding environment over a desired period of time.Type: ApplicationFiled: April 10, 2007Publication date: October 18, 2007Inventor: Dale E. Lanser
-
Publication number: 20070243238Abstract: A method for treating a mouth sore opposite a tooth by adhering an oral patch on the tooth to speed healing and relieve pain. The oral patch is placed either directly on the portion of the tooth that comes into contact with the sore or is first place onto the sore and then adhered to the tooth. The patch may be a blob of hydrophilic gums. If certain medications are applied to a mouth sore using an oral patch that delivers the medication for at least 30 minutes and the patches are used for at least two or more hours per day, the method reduces the healing time for mouth sores from typical 10-14 days to 1-5 days. The method can be used with various antimicrobials, glucocorticoids or anthihistamines incorporated into the patch that reduce inflammation or speed the healing of mouth sores.Type: ApplicationFiled: December 15, 2006Publication date: October 18, 2007Inventor: Jeffrey T. Haley
-
Patent number: 7276247Abstract: The present invention provides crosslinkable compositions useful in the preparation of hydrophilic gels, and are prepared from oligomers having pendent hydrophilic, poly(alkylene oxide) groups, pendent photoinitiator groups, and optionally polymerizable functional groups, and crosslinked by polyfunctional poly(alkylene oxides).Type: GrantFiled: April 11, 2006Date of Patent: October 2, 2007Assignee: 3M Innovative Properties CompanyInventors: Duane D. Fansler, Kevin M. Lewandowski, Michael S. Wendland, Babu N. Gaddam, Steven M. Heilmann
-
Patent number: 7276641Abstract: An aqueous hot melted type adhesive base material containing 4-biphenylyl acetic acid (BPAA) is provided. The adhesive base material contains constant amounts of BPAA and has good drug releasability, so that bioavailability of the drug is enhanced. An analgesic and anti-inflammatory external plaster containing BPAA is also provided. The plaster is obtained by dissolving BPAA into an aqueous hot melted type adhesive base material comprising as essential components a styrene-isoprene-styrene block copolymer, an adhesive resin, an antioxidant, lanolin, and water.Type: GrantFiled: September 6, 2005Date of Patent: October 2, 2007Assignee: Teikoku Seiyaku Co., Ltd.Inventor: Toshikuni Kawaji
-
Patent number: 7273619Abstract: The present invention relates to a transdermal composition of an antivomiting agent, and more particularly to a transdermal composition of an antivomiting agent which can minimize skin irritation by employing tropisetron as the antivomiting agent as well as by adjusting its pH to be in the range of 8 to 9 thus enhancing its rate of skin penetration thereby reducing the amount of a skin penetration enhancer used.Type: GrantFiled: April 15, 2003Date of Patent: September 25, 2007Assignee: Samyang CorporationInventors: Chaul Min Pai, Jin Deog Song, Joong Woong Cho
-
Patent number: 7270834Abstract: A pharmaceutical composition to be externally applied as a topical preparation for treating several diseases, the composition comprising dimethylsulfoxide (DMSO) and ozone. A method for obtaining the composition by ozonizing DMSO and a method for treating diseases by applying the composition are also provided.Type: GrantFiled: June 3, 2002Date of Patent: September 18, 2007Inventors: Haydee Alba Stenti, Claudia Pirillo, Jose Maria Pastoriza
-
Patent number: 7267829Abstract: A transdermal delivery system (TDS)for use in treatment of living bodies may be applied as an open (liquid, gel) or closed (patch) article. The TDS is composed of a particular active agent which dictates an associated selection of certain solvents, solvent modifiers, solute modifiers and skin stabilizers with which the medicament forms a true solution that rapidly crosses the skin barrier. The associated selection of the particular solvents, solvent modifiers, solute modifiers and skin stabilizers is based on a balancing of the molecular properties of all the components against the molecular properties of all the components plus the particular active agent. The TDS may also include a source of cellular energy to induce CAMP or cGMP. The TDS improves delivery of active agents having a molecular weight greater than 340 Daltons and increases dosage above 0.25 mg/day for such active agents.Type: GrantFiled: April 23, 2004Date of Patent: September 11, 2007Assignee: Transdermal Technologies, Inc.Inventors: Kenneth B Kirby, Berno Pettersson
-
Patent number: 7264823Abstract: An adhesive including a mixture of isocyanate capped molecules formed by reacting multi-isocyanate functional molecules with multi-functional precursor molecules including terminal functional groups selected from the group consisting of a hydroxyl group, a primary amino group and a secondary amino group. Preferably, the functional groups are hydroxyl groups. The multi-functional precursor compounds are biocompatible. Multi-amine functional precursors of the multi-isocyanate functional molecules are also biocompatible. As discussed, above, the mixture of molecules preferably has an average isocyanate functionality of at least 2.1 and, more preferably, has an average isocyanate functionality of at least 2.5. As also described above, the mixture of molecules preferably has a viscosity in the range of approximately 1 to approximately 100 centipoise. The mixture of molecules forms a crosslinked polymer network upon contact with the organic tissue in the presence of water.Type: GrantFiled: February 10, 2003Date of Patent: September 4, 2007Assignee: University of PittsburghInventors: Eric J. Beckman, Michael Buckley, Sudha Agarwal, Jianying Zhang
-
Patent number: 7258871Abstract: The invention relates to the use of a dopamine agonist in the form of an agent consisting of at least two spatially discrete compositions, of which one is a transdermal therapeutic system (TTS) containing the dopaminergic agent and another one or more are preparations for oral and/or parenteral application containing that same dopaminergic agent for the treatment of dopaminergically treatable diseases with the following elements: a) the TTS is continuously applied, b) within the duration of application in a) the composition for oral or parenteral dosage is administered.Type: GrantFiled: August 24, 2001Date of Patent: August 21, 2007Assignee: Neurobiotec GmbHInventors: Reinhard Horowski, Johannes Tack
-
Patent number: 7256234Abstract: The present invention is directed to a hybridized polymer matrix, a method of making such, and products incorporating such a matrix. The hybridized polymer matrix comprises a solvent-free polymer matrix base, a hybridized matrix comprising one or more poly(1-vinyl-2-pyrrolidones) and dimethyl sulfoxide, and at least one active substance. The hybridized polymer matrix is useful in the preparation of transdermal therapeutic systems, particularly making possible the introduction of pharmaceutically active substances which are otherwise difficult to dissolve, such as ibuprofen, into a non-polar matrix.Type: GrantFiled: September 22, 2004Date of Patent: August 14, 2007Assignee: Beiersdorf AGInventors: Jens Nierle, Christian Gäde
-
Patent number: 7250546Abstract: This invention provides a patch with less skin stimulation, excellent in long time store stability and heat stability and having favorable tack during use. The patch comprising a styrene-isoprene-styrene block copolymer, polyisobutylene, tackifier, plasticizer and pharmaceutically effective ingredient, in which two or more kinds of polyisobutylene of different average molecular weight are used in combination and the viscosity of the adhesive of the patch is between 1500 and 30,000 poise (at 60° C.) and the tack of the patch is from 5 to 200 g/10 mm.Type: GrantFiled: December 5, 2006Date of Patent: July 31, 2007Assignee: Hisamitsu Pharmaceuticals Co., Inc.Inventors: Kiyomi Tsuruda, Yasuhiro Ikeura
-
Publication number: 20070172519Abstract: An instant sterile adhering functional patch manufacturing machine is disclosed. This machine can be installed at any location. After a consumer deposits the coins and presses the start button, the process is then initiated at the machine. Using the internal operating mechanisms contained inside the main body, the extract solution, which has a specific formulation, is dosed onto an adhering patch under a sterile environment. And later, after the appropriate packaging and printing of the associated text or patterns, the finished packaged and printed product is delivered out of the main body to allow the consumer to instantly receive a fresh adhering functional patch.Type: ApplicationFiled: January 15, 2007Publication date: July 26, 2007Inventor: Chung-King Hsu
-
Patent number: 7247315Abstract: The invention relates to transdermal delivery patches comprising a drug-containing drug reservoir wherein the drug reservoir comprises a plasticizer composition selected to adjust the rate of drug flux out of the transdermal delivery patch device. The invention also specifically relates to methods of producing the transdermal delivery patches of the invention, the methods comprising the use of an alcohol drug dispersing agent. The invention further specifically relates to methods of treating acute and chronic pain and methods of inducing and maintaining analgesia with the transdermal delivery patches of the invention.Type: GrantFiled: August 15, 2002Date of Patent: July 24, 2007Assignee: Lavipharm Laboratories Inc.Inventors: Teletha A. Brown, James Osborne, Michael Rudella, Brian Hunt, Vinod Malik
-
Patent number: 7244447Abstract: A method is provided for increasing the permeability of skin or mucosal tissue to transdermally administered nonsteroidal anti-inflammatory drugs (NSAIDs). The method involves use of a specified amount of a hydroxide-releasing agent, the amount optimized to increase the flux of the NSAID through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. Formulations and drug delivery systems for co-administering a hydroxide-releasing agent with an NSAID are provided as well.Type: GrantFiled: July 30, 2003Date of Patent: July 17, 2007Assignee: Dermatrends, Inc.Inventors: Tsung-Min Hsu, Eric C. Luo
-
Patent number: 7238849Abstract: An adhesive dispensing arrangement (10) comprises an adhesive patch (12), a sachet (14), a sachet sealing strip (16), a pair of parallel gauze flaps (18A and 18B), and a peelable backing strip (20). The sachet houses a medicament such as an antiseptic or anti-microbial ointment (30), and the exposable surface (32) of the sachet is formed with a series of regularly spaced apertures (34) through which the ointment (30) may be dispensed. The peeling backing strip (20) and sachet sealing strip (16) are simultaneously peeled away, thereby exposing the apertures (34), with a central portion of the sealing strip being pulled through the gap between the gauze flaps (18A and 18B). The adhesive patch (12) is then applied around the affected area, with the ointment (30) and the sachet being dispensed via the apertures onto the gauze flaps and into treating contact with the wound.Type: GrantFiled: August 24, 2004Date of Patent: July 3, 2007Inventors: Barbara Sheila Goldberg, Patricia Ann Crossley, Johan Christiaan Fitter, Brian Lester Wolfowitz
-
Patent number: 7198800Abstract: Non-aerosol spray-on skin patch compositions as described comprising at least one substantially water insoluble film forming agent, at least one film plasticizer agent, at least one water soluble compound, and at least one organic solvent, the composition forming a flexible, porous and physiologically compatible skin patch when sprayed on to skin and allowed to dry. Also described are methods of improving wound healing by administering a physiologically active ingredient to a patient in need of such treatment.Type: GrantFiled: November 22, 2000Date of Patent: April 3, 2007Inventor: Thomas Sai Ying Ko
-
Patent number: 7197359Abstract: The present invention relates to compositions for electroporation which are useful in elevating percutaneous absorbability of drugs, etc. By controlling electrolyte concentration of compositions for electroporation so as to make an osmotic pressure of the compositions not more than a physical osmotic pressure, the percutaneous absorbability of drugs can be elevated.Type: GrantFiled: April 6, 2000Date of Patent: March 27, 2007Assignee: Pola Chemical Industries Inc.Inventors: Yoshihiro Tokudome, Koji Owaku, Kenichi Goto, Kenji Sugibayashi
-
Patent number: 7179483Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.Type: GrantFiled: August 6, 2004Date of Patent: February 20, 2007Assignee: Watson Pharmaceuticals, Inc.Inventors: Charles D. Ebert, Steven W. Sanders
-
Patent number: 7175853Abstract: This invention provides for a therapeutic system for timed and controlled release of at least one therapeutic active agent to a human or animal organism by diffusion through the skin or mucous membrane. The active agent is initially present, for the purposes of manufacture and storage, in a first state in the form of a pharmaceutically acceptable salt, which is chemically stable and insufficiently permeable for the skin or mucous membrane. The active agent is converted at the application site upon access of moisture and by an activating agent into a second state, which is suitable for diffusion through the skin or mucous membrane and in which it is taken up by the organism. The activating agent is initially present as a solid substance or a mixture or a plurality of such substances, which reacts in aqueous solution as an acid or base. The activating agent contains a portion of water of at least 5% in its solid body structure, either intercalated or bound thereto.Type: GrantFiled: March 18, 1999Date of Patent: February 13, 2007Assignee: LTS Lohmann Therapie-Systeme AGInventor: Stefan Bracht
-
Patent number: 7169409Abstract: An improved method for the manufacture of transdermal drug delivery devices comprising liquid dispersions of a liquid in an aqueous or nonaqueous matrix is disclosed. More particularly, the invention relates to preventing the formation of a crystalline structure in such liquid dispersions by annealing films and laminates in-line immediately following film formation and/or lamination during the manufacture of these devices.Type: GrantFiled: September 8, 2003Date of Patent: January 30, 2007Assignee: Alza CorporationInventors: John W. Dohner, Scott A. Bura
-
Patent number: 7157097Abstract: This invention lies in the technology of transdermal and topical drug delivery. In particular, the present invention relates to enhancement of the penetration of transdermally or topically applied drugs and with the reduction of skin irritation that often accompanies transdermal and topical drug delivery.Type: GrantFiled: March 12, 2003Date of Patent: January 2, 2007Assignee: Cellegy Pharmaceuticals Inc.Inventors: Vivien H. W. Mak, Stephen Grayson
-
Patent number: 7153522Abstract: Percutaneous sorbefacients comprising hexylene glycol and 1-menthol, more particularly, percutaneous sorbefacients for female hormones or derivatives thereof; and preparations for percutaneous absorption which comprise a styrene/isoprene/styrene block copolymer and/or polyisobutylene, a softener and a tackifier as the base components, hormones, in particular, follicle hormone and/or luteal hormone as the drug component and hexylene glycol and 1-menthol as a sorbefacient.Type: GrantFiled: October 14, 1999Date of Patent: December 26, 2006Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Yasuhiro Ikeura, Masayoshi Maki
-
Patent number: 7138135Abstract: Bioadhesive, closed-cell foam film, sustained release, delivery devices for administering an active agent or combination of active agents to a subject are provided. Methods for making such delivery devices and methods for using such delivery devices offering the controlled and sustained release of an active agent or combination of active agents to a subject, preferably a near zero-order release, are also provided.Type: GrantFiled: June 24, 2004Date of Patent: November 21, 2006Assignee: Lavipharm Laboratories Inc.Inventors: Li-Lan H. Chen, Li Tao, Alfred Liang, Xu Zheng
-
Patent number: 7128929Abstract: The specification discloses an alginate foam composition dressing which may be prepared with or without a backing. The foam dressing exhibits unique capability in including soluble or insoluble medicaments as part of the alginate foam composition, attributes not inherent in alginate dressings prepared by spinning. The dressings so prepared also eliminate the need for adhesives and secondary dressings for retaining an alginate dressing on a wound site.Type: GrantFiled: October 2, 2000Date of Patent: October 31, 2006Inventor: George H. Scherr
-
Patent number: 7128899Abstract: A dental bleaching composition comprises a dental bleaching agent and a polyvinylpyrrolidone thickening agent. The bleaching composition may include water, flavoring agents, a basic substance and desensitizing agents, as desired. Polyvinylpyrrolidone avoids acid etching and chelation of teeth that were problematic in bleaches using carbomer as a thickener. A delivery system for delivering the bleaching composition comprises the aforementioned dental bleaching composition in combination with a moisture-resistant barrier layer such as a dental tray or a flexible strip of material.Type: GrantFiled: November 17, 2003Date of Patent: October 31, 2006Assignee: Ultradent Products, Inc.Inventor: Tianming Chen
-
Patent number: 7118761Abstract: Wound care devices having a topically applied silver-based antimicrobial finish are provided. The finish comprises at least one silver ion-containing compound and at least one binder compound. The finish may be applied to a target substrate, such as a fiber, fabric, film, foam, hydrogel, or hydrocolloid to provide a single layer antimicrobial wound care device. Alternatively, a silver-containing layer may be combined with one or more additional layers of target substrate to provide a composite antimicrobial wound care device. The device may also contain an odor-absorbing component capable of reducing or eliminating odors that are inherently associated with infectious wounds. Also provided is a method for making the wound care device and a composition of matter comprising the silver-based antimicrobial finish.Type: GrantFiled: August 14, 2003Date of Patent: October 10, 2006Inventors: T. Andrew Canada, Robert L. Schuette, Raymond C. Sturm, Kenneth M. Wiencek, Jason L. Kreider
-
Patent number: 7115276Abstract: The present invention refers to a flat self-adhering plaster having a multi-layer construction and reduced cold flow, characterized in that the layer of adhesive possesses a core of adhesive being a flowable adhesive and a ring of adhesive being an adhesive having reduced flowability which surrounds the core.Type: GrantFiled: June 23, 2000Date of Patent: October 3, 2006Assignee: Novosis AGInventors: Wilfried Fischer, Hubert Kaffl, Petra Huber, Clifton Zimmermann
-
Patent number: 7097853Abstract: A transdermal drug delivery device involving a macromonomer-containing acrylate or methacrylate copolymer, a softener, and a drug. Also a pressure sensitive skin adhesive involving a macromonomer containing acrylate or methacrylate copolymer and a softener.Type: GrantFiled: November 12, 1997Date of Patent: August 29, 2006Assignee: 3M Innovative Properties CompanyInventors: James E. Garbe, Daniel C. Duan, Cheryl L. Moore, Jamieson C. Keister, Chan U. Ko
-
Patent number: 7094422Abstract: The present invention provides a topical drug delivery system which comprises: a therapeutically effective amount of an antifungal agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and a volatile liquid. The invention also provides a method for administering at least one systemic acting antifungal agent to an animal which comprises applying an effective amount of the antifungal agent in the form of the drug delivery system of the present invention.Type: GrantFiled: August 20, 2003Date of Patent: August 22, 2006Assignee: Acrux DDS PTY Ltd.Inventors: Nora Yat Knork Chew, Barry Leonard Reed, Timothy Matthias Morgan, Barrie Charles Finnin
-
Patent number: 7094421Abstract: It is provided the plaster of anti-inflammatory and analgesic, improving the sustained releasing of 4-biphenylacetic acid from the base adhesive material and low skin irritation, by using more than two kinds of resolvent for 4-biphenylacetic acid having low solubility in solvents. More specifically, it is provided plasters essentially containing 5–50% by weight of styrene-isoprene-styrene block copolymer, 0.05–20% by weight of N-methyl-2-pyrrolidone, 0.1–20% by weight of polyethylene glycol and 0.1–20% by weight of 4-biphenylacetic acid.Type: GrantFiled: May 31, 2001Date of Patent: August 22, 2006Assignee: Teikoku Seiyaki Co., Ltd.Inventors: Mitsuji Akazawa, Katsuyuki Inoo, Masahiro Yamaji
-
Patent number: RE39588Abstract: A diffusional drug delivery device is described which can provide for stability of the adhesive and system components, elimination of the initial burst of drug and hence irritation, and to provide for delayed onset of therapeutic effect along with delivery of a therapeutic agent at an optimum rate. The therapeutic agent in a first form which is suitable for storage, and the anhydrous activating means are inert when in an anhydrous environment. Moisture activates the system whereby the activating means provides an acidic or basic solution and the first form of the therapeutic agent is converted to a second form which is suitable for absorption through the skin or mucosa.Type: GrantFiled: October 31, 1990Date of Patent: April 24, 2007Assignee: Alza CorporationInventors: Eun Soo Lee, Su Il Yum